JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Skip to the beginning of the images gallery

Mfg Part Number

Ab01687-10.0

Vector Labs Ab01687-10.0 Anti-CD80 [7C10], Human IgG1, lambda (200 μg)

VECTOR LABS

Be the first to review this product

Quick Overview

This antibody was generated by immunization of cynomolgus monkeys with human B7.1 antigen.

$517.40

Order will ship within 1-3 business days

Description

Product Class: Purified
Clone ID: 7C10
Synonyms: B7.1; CD28L; CD28LG; B7-1; B7; BB1; B7/BB1;T-lymphocyte activation antigen CD80; Activation B7-1 antigen; CTLA-4 counter-receptor B7.1; CTLA4L; CTLA-4L
Amount: 200 μg
Application Codes Clone: Block; ELISA; Therapeutic
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG1
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody binds human CD80 and inhibits the B7.1:CD28 pathway.
Application Notes: This antibody can be used for identification of human B7.1 antigen and is capable of inhibiting the binding of B7.1 to CD28, however it does not block the binding of B7.1 to CTLA-4. This antibody further inhibits the production of IL-2. Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signaling. The binding of the antibody to soluble B7.1 was tested using ELISA. This antibody tested positive for binding to human C1q protein. This antibody is reported to cause keratinocyte hyperproliferation and decrease in psoriasis by inhibiting the B7:CD28 pathway. This antibody is further reported to be useful for the treatment of intestinal inflammation and rheumatoid arthritis.

Product Class:	Purified
Clone ID:	7C10
Synonyms:	B7.1; CD28L; CD28LG; B7-1; B7; BB1; B7/BB1;T-lymphocyte activation antigen CD80; Activation B7-1 antigen; CTLA-4 counter-receptor B7.1; CTLA4L; CTLA-4L
Amount:	200 μg
Application Codes Clone:	Block; ELISA; Therapeutic
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG1
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement:	This antibody binds human CD80 and inhibits the B7.1:CD28 pathway.
Application Notes:	This antibody can be used for identification of human B7.1 antigen and is capable of inhibiting the binding of B7.1 to CD28, however it does not block the binding of B7.1 to CTLA-4. This antibody further inhibits the production of IL-2. Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signaling. The binding of the antibody to soluble B7.1 was tested using ELISA. This antibody tested positive for binding to human C1q protein. This antibody is reported to cause keratinocyte hyperproliferation and decrease in psoriasis by inhibiting the B7:CD28 pathway. This antibody is further reported to be useful for the treatment of intestinal inflammation and rheumatoid arthritis.

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews